Tandem Diabetes Care Inc. plans to offer and sell its common shares, series A warrants and series B warrants to buy common shares in an underwritten public offering.

The company plans to use the net proceeds for working capital and other general corporate purposes.

Oppenheimer & Co. Inc. is acting as the sole book-running manager and National Securities Corp. is acting as a co-manager for the offering.